ACST:NSD-Acasti Pharma Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 0.43

Change

-0.02 (-3.99)%

Market Cap

USD 0.09B

Volume

5.82M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. Its lead product candidate is CaPre, an omega-3 phospholipid therapeutic that is in Phase III clinical trial to treat patients with hypertriglyceridemia; and TRILOGY that is in Phase III to evaluate the safety and efficacy of CaPre in patients with sHTG. The company was incorporated in 2002 and is headquartered in Laval, Canada.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-05-05 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

-10.75 (-6.19%)

USD69.53B N/A N/A
VRTX Vertex Pharmaceuticals Incorpo..

-0.98 (-0.46%)

USD55.62B 20.48 15.19
REGN Regeneron Pharmaceuticals, Inc

-2.76 (-0.57%)

USD51.68B 15.90 12.28
BNTX BioNTech SE

-6.11 (-3.45%)

USD50.45B -99,999.99 N/A
ALXN Alexion Pharmaceuticals, Inc

+1.42 (+0.84%)

USD37.30B 54.77 36.21
BGNE BeiGene, Ltd

-4.85 (-1.56%)

USD29.11B N/A N/A
RPRX Royalty Pharma plc

-0.65 (-1.53%)

USD25.78B 22.60 15.82
SGEN Seagen Inc

-1.11 (-0.82%)

USD24.72B 38.00 35.77
GMAB Genmab A/S

+1.09 (+3.06%)

USD24.27B 26.59 3.52
CVAC CureVac N.V

-7.93 (-7.27%)

USD22.38B N/A N/A

ETFs Containing ACST

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 29.94% 81% B- 78% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 29.94% 81% B- 78% C+
Trailing 12 Months  
Capital Gain -29.12% 24% F 7% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -29.12% 24% F 7% F
Trailing 5 Years  
Capital Gain -68.00% 24% F 8% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -68.00% 24% F 7% F
Average Annual (5 Year Horizon)  
Capital Gain 4.35% 40% F 45% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.35% 40% F 40% F
Risk Return Profile  
Volatility (Standard Deviation) 88.57% 32% F 18% F
Risk Adjusted Return 4.91% 36% F 28% F
Market Capitalization 0.09B 16% F 18% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 16.41 36% F 56% F
Price/Book Ratio 3.84 60% D- 44% F
Price / Cash Flow Ratio -55.51 93% A 92% A-
EV/EBITDA 16.42 26% F 53% F
Management Effectiveness  
Return on Equity 24.66% 97% A+ 92% A-
Return on Invested Capital -196.99% 6% F 3% F
Return on Assets -28.31% 46% F 14% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.27 94% A 87% B+
Short Percent 1.49% 92% A- 75% C
Beta 1.50 44% F 30% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector